Sangamo Therapeutics, Inc (SGMOQ): Capital Expenditures
$102.0K
Year ended 2025-12-31
$115.0K
Trailing 12 months to 2026-03-31
-82.8%
3-year compound annual growth
-63.0%
5-year compound annual growth
-27.1%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $102.0K | -61.8% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $267.0K | -98.7% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $21.16M | +4.9% | 2025-03-17, From 2023-01-01 |
| 2022-12-31 | $20.17M | -13.3% | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $23.28M | +58.2% | 2024-03-13, From 2021-01-01 |
| 2020-12-31 | $14.71M | -28.8% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $20.68M | -52.0% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $43.06M | n/m | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $3.75M | +412.4% | 2020-02-28, From 2017-01-01 |
| 2016-12-31 | $732.0K | -69.6% | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | $2.41M | +288.2% | 2016-02-18, From 2015-01-01 |
| 2014-12-31 | $621.0K | +43.8% | 2016-02-18, From 2014-01-01 |
| 2013-12-31 | $432.0K | -40.2% | 2016-02-18, From 2013-01-01 |
| 2012-12-31 | $723.0K | +25.5% | 2015-02-25, From 2012-01-01 |
| 2011-12-31 | $576.0K | -17.1% | 2014-02-24, From 2011-01-01 |
| 2010-12-31 | $695.0K | +155.5% | 2013-02-26, From 2010-01-01 |
| 2009-12-31 | $272.0K | n/a | 2012-02-23, From 2009-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $102.0K | -61.8% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.45M | -88.7% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $2.60M | -26.3% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $607.0K | -93.1% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $607.0K | +237.2% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $0 | -100.0% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $85.0K | -66.0% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $133.0K | n/a |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $1.64M | +27.8% |
Compare SGMOQ, KYMR, VYGR, EDIT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗